

**In the Claims:**

Claims 1-24 (Cancelled)

25. (Currently Amended): An isolated, recombinant polypeptide comprising a member selected from the group consisting of

- (a) ~~the an~~ amino acid sequence ~~comprising the sequence set forth in~~ SEQ ID NO:2;
- (b) an immunogenic ~~polypeptide comprising a~~ fragment ~~sequence~~ of at least 15 contiguous amino acids ~~that corresponds to an aligned contiguous segment of~~ SEQ ID NO:2;

wherein the immunogenic fragment ~~isolated polypeptide~~, when administered to a subject in a suitable composition which can include an adjuvant, or a suitable carrier coupled to the polypeptide, induces an antibody or T-cell mediated immune response that recognizes the ~~to a~~ polypeptide ~~having the sequence of~~ SEQ ID NO:2.

26. (Cancelled)

27. (Currently Amended): The isolated, recombinant polypeptide of claim 25, wherein the polypeptide is according to (a).

28. (Cancelled)

29. (Currently Amended): The isolated, recombinant polypeptide of claim 25, wherein the polypeptide is according to (b).

30. (Cancelled)

31. (Currently Amended): The isolated, recombinant polypeptide of claim 25, wherein the immunogenic fragment of (b) comprises at least 20 contiguous amino acids of SEQ ID NO:2, wherein the immunogenic fragment, when administered to a subject in a suitable composition

which can include an adjuvant, or a suitable carrier coupled to the polypeptide, induces an antibody or T-cell mediated immune response that recognizes the polypeptide SEQ ID NO:2.

32. (Currently Amended): The isolated, recombinant polypeptide of Claim 25 wherein the isolated polypeptide of (a) consists of SEQ ID NO:2.

Claims 33-34 (Cancelled)

35. (Currently Amended): A fusion protein comprising the isolated, recombinant polypeptide of Claim 25.

Claims 36-39 (Cancelled)

40. (Currently Amended): An immunogenic composition comprising the isolated, recombinant polypeptide of Claim 25 and a pharmaceutically acceptable carrier.

41. (Previously Presented): The immunogenic composition of Claim 40, wherein the immunogenic composition comprises at least one other *Neisseria meningitidis* antigen in addition to an antigen provided by the polypeptide.

42. (Cancelled)

43. (Currently Amended): A method for inducing an immune response in a mammal comprising administration of the polypeptide of Claim 25.

Claims 44-46 (Cancelled)

47. (New): An isolated polypeptide consisting of the amino acid sequence SEQ ID NO:2.